{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T07:45:55Z","timestamp":1791963955243,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtct.2026.09.008","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:43:11Z","timestamp":1789882991000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Associations of Molecular MRD and Genomic Features in ZNF384-Rearranged B-ALL Undergoing Allo-HSCT"],"prefix":"10.1016","author":[{"given":"Xue-Shuang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Yu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Juan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Jie","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Rui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7964-3181","authenticated-orcid":false,"given":"Jing","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jtct.2026.09.008_bib0001","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1038\/s41375-021-01199-0","article-title":"Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group","volume":"35","author":"Hirabayashi","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.008_bib0002","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3324\/haematol.2016.151035","article-title":"ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype","volume":"102","author":"Hirabayashi","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2026.09.008_bib0003","doi-asserted-by":"crossref","DOI":"10.1177\/10732748231182787","article-title":"ZNF384-related fusion genes in acute lymphoblastic leukemia","volume":"30","author":"Zhu","year":"2023","journal-title":"Cancer Control"},{"issue":"12","key":"10.1016\/j.jtct.2026.09.008_bib0004","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2017-05-742643","article-title":"New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"130","author":"Lilljebj\u00f6rn","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.09.008_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2019.101095","article-title":"How advanced are we in targeting novel subtypes of ALL?","volume":"32","author":"Mullighan","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"10.1016\/j.jtct.2026.09.008_bib0006","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2643-3230.BCD-20-0229","article-title":"Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy","volume":"2","author":"Jeha","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"2","key":"10.1016\/j.jtct.2026.09.008_bib0007","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/10428194.2022.2148217","article-title":"ZNF384 rearrangement is the most frequent genetic lesion in adult PH-negative and Ph-like-negative B-other acute lymphoblastic leukemia. Biological and clinical findings","volume":"64","author":"Chiaretti","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"29","key":"10.1016\/j.jtct.2026.09.008_bib0008","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1200\/JCO.23.02238","article-title":"Genomic determinants of outcome in acute lymphoblastic leukemia","volume":"42","author":"Chang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.jtct.2026.09.008_bib0009","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1200\/JCO.22.02705","article-title":"Improved outcome for ALL by prolonging therapy for IKZF1 deletion and decreasing therapy for other risk groups","volume":"41","author":"Pieters","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2026.09.008_bib0010","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.3324\/haematol.2023.284357","article-title":"IKZF1 gene deletions drive resistance to cytarabine in B-cell precursor acute lymphoblastic leukemia","volume":"109","author":"Vervoort","year":"2024","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.jtct.2026.09.008_bib0011","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/bloodadvances.2018027003","article-title":"The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia","volume":"3","author":"Yeshurun","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.09.008_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.796994","article-title":"Is it possible to separate the graft-versus-leukemia (GVL) effect against B cell acute lymphoblastic leukemia from graft-versus-host disease (GVHD) after hematopoietic cell transplant?","volume":"10","author":"Rozmus","year":"2022","journal-title":"Front Pediatr"},{"issue":"19","key":"10.1016\/j.jtct.2026.09.008_bib0013","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood.2023020794","article-title":"Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"G\u00f6kbuget","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2026.09.008_bib0014","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.09.008_bib0015","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1158\/2643-3230.BCD-21-0163","article-title":"ZNF384 fusion oncoproteins drive lineage aberrancy in acute leukemia","volume":"3","author":"Dickerson","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"11","key":"10.1016\/j.jtct.2026.09.008_bib0016","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/bloodadvances.2022008981","article-title":"CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany","volume":"7","author":"Bader","year":"2023","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.jtct.2026.09.008_bib0017","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.09.008_bib0018","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.09.008_bib0019","article-title":"Leukemia with TCF3-ZNF384 rearrangement as a distinct subtype of disease with distinct treatments: perspectives from a case report and literature review","volume":"11","author":"Lin","year":"2021","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2026.09.008_bib0020","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.008_bib0021","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.09.008_bib0022","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.09.008_bib0023","article-title":"The prognostic significance of ZNF384 fusions in adult Ph-negative B-cell precursor acute lymphoblastic leukemia: a comprehensive cohort study from a single Chinese center","volume":"11","author":"Qin","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.008_bib0024","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3251","article-title":"ZNF384 fusion transcript levels for measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia","volume":"42","author":"Shi","year":"2024","journal-title":"Hematol Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2026.09.008_bib0025","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.3324\/haematol.2022.280638","article-title":"Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients","volume":"107","author":"Saygin","year":"2022","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.jtct.2026.09.008_bib0026","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2002.3311a.x","article-title":"Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation","volume":"116","author":"S\u00e1nchez","year":"2002","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.008_bib0027","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1186\/s12885-018-4670-5","article-title":"Influence of pre-transplant minimal residual disease on prognosis after allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis","volume":"18","author":"Shen","year":"2018","journal-title":"BMC Cancer"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726007086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726007086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:58:16Z","timestamp":1791961096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726007086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"alternative-id":["S2666636726007086"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.09.008","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Associations of Molecular MRD and Genomic Features in ZNF384-Rearranged B-ALL Undergoing Allo-HSCT","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}